Hormone receptor (HR)-positive / HER2-negative breast cancer is the most prevalent breast cancer subtype. Targeted therapies aimed at CDK4/6 inhibition (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) have changed the treatment landscape because they are particularly effective when combined with hormonal agents. The approval of biomarker-driven therapies has also broadened the treatment armamentarium, which now includes two PARP inhibitors (AstraZeneca’s Lynparza and Pfizer’s Talzenna) for germline BRCA mutation-positive HER2-negative (including HR-positive) breast cancer; a PI3K inhibitor (Novartis’s Piqray) for advanced PIK3CA mutation-positive HR-positive/HER2-negative breast cancer; and the Menarini Group’s oral SERD Orserdu for previously treated ESR1-mutant metastatic patients with ER-positive, HER2-negative disease. The TROP2-targeted antibody-drug conjugate Trodelvy (AstraZeneca) has expanded treatment options in the third- and later-line metastatic setting for HR-positive/HER2-negative breast cancer, and the labels of some targeted therapies have been expanded to include the adjuvant setting (i.e., Verzenio and Lynparza), improving treatment options for early-stage disease.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 100 medical oncologists in the United States fielded in March 2023.
Key drugs: Ibrance, Kisqali, Verzenio, Lynparza, Piqray, Talzenna, Afinitor, fulvestrant, Orserdu, Trodelvy.